Literature DB >> 23180358

Laboratory testing for prescription opioids.

Michael C Milone1.   

Abstract

Opioid analgesic misuse has risen significantly over the past two decades, and these drugs now represent the most commonly abused class of prescription medications. They are a major cause of poisoning deaths in the USA exceeding heroin and cocaine. Laboratory testing plays a role in the detection of opioid misuse and the evaluation of patients with opioid intoxication. Laboratories use both immunoassay and chromatographic methods (e.g., liquid chromatography with mass spectrometry detection), often in combination, to yield high detection sensitivity and drug specificity. Testing methods for opioids originated in the workplace-testing arena and focused on detection of illicit heroin use. Analysis for a wide range of opioids is now required in the context of the prescription opioid epidemic. Testing methods have also been primarily based upon urine screening; however, methods for analyzing alternative samples such as saliva, sweat, and hair are available. Application of testing to monitor prescription opioid drug therapy is an increasingly important use of drug testing, and this area of testing introduces new interpretative challenges. In particular, drug metabolism may transform one clinically available opioid into another. The sensitivity of testing methods also varies considerably across the spectrum of opioid drugs. An understanding of opioid metabolism and method sensitivity towards different opioid drugs is therefore essential to effective use of these tests. Improved testing algorithms and more research into the effective use of drug testing in the clinical setting, particularly in pain medicine and substance abuse, are needed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23180358      PMCID: PMC3550258          DOI: 10.1007/s13181-012-0274-7

Source DB:  PubMed          Journal:  J Med Toxicol        ISSN: 1556-9039


  94 in total

1.  Identification of fentanyl, alfentanil, sufentanil, remifentanil and their major metabolites in human urine by liquid chromatography/tandem mass spectrometry for doping control purposes.

Authors:  Mario Thevis; Hans Geyer; Daniel Bahr; Wilhelm Schänzer
Journal:  Eur J Mass Spectrom (Chichester)       Date:  2005       Impact factor: 1.067

2.  Evaluation of the usefulness of an oxycodone immunoassay in combination with a traditional opiate immunoassay for the screening of opiates in urine.

Authors:  Marie Gingras; Marie-Hélène Laberge; Michel Lefebvre
Journal:  J Anal Toxicol       Date:  2010-03       Impact factor: 3.367

Review 3.  Opioid epidemic in the United States.

Authors:  Laxmaiah Manchikanti; Standiford Helm; Bert Fellows; Jeffrey W Janata; Vidyasagar Pampati; Jay S Grider; Mark V Boswell
Journal:  Pain Physician       Date:  2012-07       Impact factor: 4.965

4.  Direct-injection mass spectrometric method for the rapid identification of fentanyl and norfentanyl in postmortem urine of six drug-overdose cases.

Authors:  Cody J Peer; Diaa M Shakleya; Islam R Younis; James C Kraner; Patrick S Callery
Journal:  J Anal Toxicol       Date:  2007-10       Impact factor: 3.367

5.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

6.  Development and validation of the Current Opioid Misuse Measure.

Authors:  Stephen F Butler; Simon H Budman; Kathrine C Fernandez; Brian Houle; Christine Benoit; Nathaniel Katz; Robert N Jamison
Journal:  Pain       Date:  2007-05-09       Impact factor: 6.961

7.  Prevalence of dihydrocodeine in hydrocodone positive postmortem specimens.

Authors:  Amanda J Jenkins; Eric S Lavins; Courtney Hunek
Journal:  J Forensic Leg Med       Date:  2008-09-26       Impact factor: 1.614

8.  Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS.

Authors:  S Hegstad; H Z Khiabani; E L Øiestad; T Berg; A S Christophersen
Journal:  J Anal Toxicol       Date:  2007-05       Impact factor: 3.367

9.  Drug testing of adolescents in ambulatory medicine: physician practices and knowledge.

Authors:  Sharon Levy; Sion Kim Harris; Lon Sherritt; Michelle Angulo; John R Knight
Journal:  Arch Pediatr Adolesc Med       Date:  2006-02

10.  Urinary buprenorphine concentrations in patients treated with suboxone as determined by liquid chromatography-mass spectrometry and CEDIA immunoassay.

Authors:  Mindy J Hull; Michael F Bierer; David A Griggs; William H Long; Andrea L Nixon; James G Flood
Journal:  J Anal Toxicol       Date:  2008-09       Impact factor: 3.367

View more
  18 in total

Review 1.  Maternity Care for Pregnant Women with Opioid Use Disorder: A Review.

Authors:  Abigail H Rizk; Sara E Simonsen; Leissa Roberts; Lisa Taylor-Swanson; Jennifer Berkowicz Lemoine; Marcela Smid
Journal:  J Midwifery Womens Health       Date:  2019-08-12       Impact factor: 2.388

2.  The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015.

Authors:  Alexander Y Walley; Dana Bernson; Marc R Larochelle; Traci C Green; Leonard Young; Thomas Land
Journal:  Public Health Rep       Date:  2019-10-02       Impact factor: 2.792

3.  Automatic Detection of Opioid Intake Using Wearable Biosensor.

Authors:  Md Shaad Mahmud; Hua Fang; Honggang Wang; Stephanie Carreiro; Edward Boyer
Journal:  Int Conf Comput Netw Commun       Date:  2018-06-21

Review 4.  Characterizing the Interrelationships of Prescription Opioid and Benzodiazepine Drugs With Worker Health and Workplace Hazards.

Authors:  Michele Kowalski-McGraw; Judith Green-McKenzie; Sudha P Pandalai; Paul A Schulte
Journal:  J Occup Environ Med       Date:  2017-11       Impact factor: 2.162

5.  Comparison of Response of DRI Oxycodone Semiquantitative Immunoassay With True Oxycodone Values Determined by Liquid Chromatography Combined With Tandem Mass Spectrometry: Sensitivity of the DRI Assay at 100 ng/ml Cut-Off and Validity of Semiquantitative Value.

Authors:  R Brent Dixon; Bonnette Davis; Amitava Dasgupta
Journal:  J Clin Lab Anal       Date:  2015-02-25       Impact factor: 2.352

6.  The epidemiology of prescription fentanyl misuse in the United States.

Authors:  Ty S Schepis; Vita V McCabe; Carol J Boyd; Sean Esteban McCabe
Journal:  Addict Behav       Date:  2019-04-22       Impact factor: 3.913

7.  Quantitative and rapid detection of morphine and hydromorphone at the point of care by an automated giant magnetoresistive nanosensor platform.

Authors:  Dana L Cortade; Shan X Wang
Journal:  Anal Bioanal Chem       Date:  2022-08-19       Impact factor: 4.478

Review 8.  Dependence on Prescription Opioids.

Authors:  Johannes Just; Martin Mücke; Markus Bleckwenn
Journal:  Dtsch Arztebl Int       Date:  2016-04-01       Impact factor: 5.594

9.  The Rapid Escalation of Fentanyl in Illicit Drug Evidence in Allegheny County, Pennsylvania, 2010-2016.

Authors:  Kathleen E Creppage; Joshua Yohannan; Karl Williams; Jeanine M Buchanich; Thomas J Songer; Stephen R Wisniewski; Anthony Fabio
Journal:  Public Health Rep       Date:  2018-02-01       Impact factor: 2.792

Review 10.  Opioids in Hemodialysis Patients.

Authors:  Sahir Kalim; Karen S Lyons; Sagar U Nigwekar
Journal:  Semin Nephrol       Date:  2021-01       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.